grt-r902
Biologicalexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Oct 31, 2018 (NCT03639714)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
Tumor antigens immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05456165 | Phase 2 | May 19, 2022 | Gritstone Oncology, Inc. |
| NCT05141721 | Phase 2/Phase 3 (Phase 3) | Feb 28, 2022 | Gritstone Oncology, Inc. |
| NCT03639714 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2018 | Bristol-Myers Squibb, Gritstone Oncology, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gritstone Oncology, Inc. | For profit | 3 | 3 | 2 | 2018 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1